trending Market Intelligence /marketintelligence/en/news-insights/trending/83UglRgt5PXVH5fQ91Y4pA2 content esgSubNav
In This List

Achaogen's plazomicin phase 3 trials meet US FDA and EMA endpoints

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Achaogen's plazomicin phase 3 trials meet US FDA and EMA endpoints

Achaogen Inc.'s lead product plazomicin achieved U.S. FDA primary endpoints in patients with complicated urinary tract infections and acute pyelonephritis, compared to meropenem.

Plazomicin is being developed to treat serious bacterial infections due to multidrug-resistant enterobacteriaceae. The drug also demonstrated superiority for the European Medicines Agency-specified primary efficacy endpoints in the phase 3 EPIC registration trial in patients with cUTI.

In addition, plazomicin performed well in the phase 3 CARE trial in patients with serious infections due to carbapenem-resistant enterobacteriaceae, an antibiotic resistant bacteria, showing a 71% relative reduction in mortality compared with therapy with antibiotic colistin.

The company plans to submit a new drug application to the FDA in the second half of 2017 and a marketing authorization application to the EMA in 2018.